Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.
They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.
This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.
The Freely Filtered team (minus Samira) spent an hour doing a deep dive on the Risk Score for IgA nephropathy and how many grams of IgA a human makes everyday.
Listen
Subscribe
Leave a review on iTunes.
NSMC Intern Daniyal Jafree stepped up to write an excellent tweetorial on the latest NephJC discussion. Take a look.
Welcome to the @NSMCInternship #tweetorial for this week’s study on a new risk prediction tool for IgA nephropathy, appearing in @JAMAInternalMed. Check out these unhappy glomeruli with mesangial IgA deposits in green from https://t.co/5t2NImFGj4 (1/16) pic.twitter.com/nDEkuxduK6
— Nephrology Jrnl Club (@NephJC) June 3, 2019
